| Citation: |
GAN Bin, LIU Si-yang, YAN Hong-hong, WU Yi-long. Current Situation Investigation of Clinical Diagnosis and Treatment of Non-Small Cell Lung Cancer With MET Alterations in China[J]. Journal of Evidence-Based Medicine, 2024, 24(2): 97-106. DOI: 10.12019/j.issn.1671-5144.202401019
|
Mesenchymal epithelial transition (MET) factor alteration in non-small cell lung cancer (NSCLC) mainly includes MET exon 14 skipping alteration (METex14 skipping), MET gene amplification, and MET protein overexpression, etc. METex14 skipping is a driver gene mutation in advanced NSCLC, and the incidence of METex14 skipping in NSCLC patients was 0.9%~4%. Currently, several drugs targeting METex14 skipping have been approved in China and other countries. The incidence of de novo MET gene amplification in NSCLC patients was 1%~5%, which was associated with poor prognosis. MET gene amplification is more frequently occurring after targeted therapy in NSCLC patients with other positive driver genes and is one of the important mechanisms of EGFR-TKI resistance. The purpose of this study is to understand the status of diagnosis and treatment of NSCLC patients with MET alterations in China, including awareness of physicians on MET inhibitors, considerations for treatment decisions of NSCLC patients with MET alterations, and to explore the unmet needs in clinical practice.
Physicians who had treated MET alteration patients within a defined period participated in the survey through the online questionnaire, and the results were summarized and descriptively analyzed.
A total of 140 valid questionnaires were collected. For METex14 skipping NSCLC, MET-TKI monotherapy was preferred by more than 50% of the physicians interviewed, regardless of whether patients were treatment naïve or pretreated. The incidence of grade ≥3 adverse events (AE) was the most concerned safety indicator, and the most concerned AEs included pneumonia, hepatotoxicity, and gastrointestinal AEs, etc. Peripheral edema caused by MET-TKI was of low concern. For MET-amplified EGFR mutant (EGFRm) NSCLC after EGFR-TKI resistance, the interviewed physicians preferred MET-TKI and EGFR-TKI dual-targeted combination therapy. More sufficient evidence from large-scale randomized controlled studies, standardized testing, and clinical consensus were the major unmet needs for MET-amplified EGFRm NSCLC after EGFR-TKI resistance.
The preferred proportion of MET-TKI therapy in METex14 skipping NSCLC remains to be improved, and more attention should be paid to MET-TKI-induced peripheral edema to help better management. Testing for different types of MET alteration requires further standardization and normalization.
| [1] |
FUJINO T, SUDA K, MITSUDOMI T. Lung cancer with MET exon 14 skipping mutation: genetic feature, current treatments, and future challenges[J]. Lung Cancer (Auckl), 2021, 12: 35−50. doi: 10.2147/LCTT.S269307.
|
| [2] |
Chinese Society of Pathology, Pathology Quality Control Center, Lung Cancer Group of Chinese Medical Association Chinese Society of Oncology, et al. Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer[J]. Chinese Journal of Pathology, 2022, 51(11): 1094−1103. [中华医学会病理学分会, 国家病理质控中心, 中华医学会肿瘤学分会肺癌学组, 等. 非小细胞肺癌MET临床检测中国专家共识[J]. 中华病理学杂志, 2022, 51(11): 1094−1103] doi: 10.3760/cma.j.cn112151-20220606-00491.
Chinese Society of Pathology, Pathology Quality Control Center, Lung Cancer Group of Chinese Medical Association Chinese Society of Oncology, et al. Chinese expert consensus on clinical practice of MET detection in non-small cell lung cancer[J]. Chinese Journal of Pathology, 2022, 51(11): 1094−1103. doi: 10.3760/cma.j.cn112151-20220606-00491
|
| [3] |
COLEMAN N, HONG L, ZHANG J, et al. Beyond epidermal growth factor receptor: MET amplification as a general resistance driver to targeted therapy in oncogene-driven non-small-cell lung cancer[J]. ESMO Open, 2021, 6(6): 100319. doi: 10.1016/j.esmoop.2021.100319.
|
| [4] |
MAZIERES J, PAIK P K, GARASSINO M C, et al. Tepotinib treatment in patients with MET Exon 14-skipping non-small cell lung cancer: long-term follow-up of the VISION Phase 2 nonrandomized clinical trial[J]. JAMA Oncol, 2023, 9(9): 1260−1266. doi: 10.1001/jamaoncol.2023.1962.
|
| [5] |
WOLF J, SETO T, HAN J Y, et al. Capmatinib in MET exon 14-mutated or MET-amplified non-small-cell lung cancer[J]. N Engl J Med, 2020, 383(10): 944−957. doi: 10.1056/NEJMoa2002787.
|
| [6] |
LU S, FANG J, LI X Y, et al. Once-daily savolitinib in Chinese patients with pulmonary sarcomatoid carcinomas and other non-small-cell lung cancers harbouring MET exon 14 skipping alterations: a multicentre, single-arm, open-label, phase 2 study[J]. Lancet Respir Med, 2021, 9(10): 1154−1164. doi: 10.1016/S2213-2600(21)00084-9.
|
| [7] |
YU Y F, ZHOU J Y, LI X Y, et al. Gumarontinib in patients with non-small-cell lung cancer harbouring MET exon 14 skipping mutations: a multicentre, single-arm, open-label, phase 1b/2 trial[J]. EClinicalMedicine, 2023, 59: 101952. doi: 10.1016/j.eclinm.2023.101952.
|
| [8] |
YANG J J, ZHANG Y, WU L, et al. 1379P Preliminary results of phase II KUNPENG study of vebreltinib in patients (Pts) with advanced NSCLC harboring c-MET alterations[J]. Ann Oncol, 2023, 34(S2): S791. doi: 10.1016/J.ANNONC.2023.09.2412.
|
| [9] |
Chinese Society of Clinical Oncology Guidelines Working Committee. Guidelines of Chinese Society of Clinical Oncology (CSCO) non-small cell lung cancer[M]. Beijing: People's Medical Publishing House, 2023. [中国临床肿瘤学会指南工作委员会. 中国临床肿瘤学会(CSCO)非小细胞肺癌诊疗指南-2023[M]. 北京: 人民卫生出版社, 2023.]
Chinese Society of Clinical Oncology Guidelines Working Committee. Guidelines of Chinese Society of Clinical Oncology (CSCO) non-small cell lung cancer[M]. Beijing: People's Medical Publishing House, 2023.
|
| [10] |
LIAM C K, AHMAD A R, HSIA T C, et al. Randomized trial of tepotinib plus gefitinib versus chemotherapy in EGFR-mutant NSCLC with EGFR inhibitor resistance due to MET amplification: INSIGHT final analysis[J]. Clin Cancer Res, 2023, 29(10): 1879−1886. doi: 10.1158/1078-0432.CCR-22-3318.
|
| [11] |
HARTMAIER R J, MARKOVETS A A, AHN M J, et al. Osimertinib + savolitinib to overcome acquired MET-mediated resistance in epidermal growth factor receptor-mutated, MET-amplified non-small cell lung cancer: TATTON[J]. Cancer Discov, 2023, 13(1): 98−113. doi: 10.1158/2159-8290.CD-22-0586.
|
| [12] |
KIM T M, GUARNERI V, JYE V P, et al. OA21.05 Tepotinib + osimertinib in EGFR-mutant NSCLC with MET amplification following 1L osimertinib: INSIGHT 2 primary analysis[J]. J Thorac Oncol, 2023, 18(11S): S94. doi: 10.1016/j.jtho.2023.09.106.
|
| [13] |
AHN M J, DE MARINIS F, BONANNO L, et al. EP08.02-140 MET biomarker-based preliminary efficacy analysis in SAVANNAH: savolitinib+osimertinib in EGFRm NSCLC post-osimertinib[J]. J Thorac Oncol, 2022, 17(9S): S469−S470. doi: 10.1016/j.jtho.2022.07.823.
|
| [14] |
WU Y L, ZHANG L, KIM D W, et al. Phase Ib/II study of capmatinib (INC280) plus gefitinib after failure of epidermal growth factor receptor (EGFR) inhibitor therapy in patients with EGFR-mutated, MET factor-dysregulated non-small-cell lung cancer[J]. J Clin Oncol, 2018, 36(31): 3101−3109. doi: 10.1200/JCO.2018.77.7326.
|
| [15] |
Rankings of Cities‘ Business Attractiveness in China 2023 [EB/OL]. (2023-05-30). [第一财经新一线城市研究所2023版《城市商业魅力排行榜》[EB/OL]. (2023-05-30). https://www.datayicai.com/report/detail/999638.]
Rankings of Cities‘ Business Attractiveness in China 2023 [EB/OL]. (2023-05-30).
|
| [16] |
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for Non-Small Cell Lung Cancer, 2023 version 5[EB/OL]. https://www.nccn.org/
|
| [17] |
Chinese Society of Pathology, Pathology Quality Control Center, Chinese Medical Association Chinese Society of Oncology, et al. Guidelines on clinical practice of molecular tests in non-small cell lung cancer in China[J]. Chinese Journal of Pathology, 2021, 50(4): 323−332. [中华医学会病理学分会, 国家病理质控中心, 中华医学会肿瘤学分会肺癌学组, 等. 非小细胞肺癌分子病理检测临床实践指南(2021版)[J]. 中华病理学杂志, 2021, 50(4): 323−332] doi: 10.3760/cma.j.cn112151-20201220-00945.
Chinese Society of Pathology, Pathology Quality Control Center, Chinese Medical Association Chinese Society of Oncology, et al. Guidelines on clinical practice of molecular tests in non-small cell lung cancer in China[J]. Chinese Journal of Pathology, 2021, 50(4): 323−332. doi: 10.3760/cma.j.cn112151-20201220-00945
|
| [18] |
LEE J K, MADISON R, CLASSON A, et al. Characterization of non-small-cell lung cancers with MET Exon 14 skipping alterations detected in tissue or liquid: clinicogenomics and real-world treatment patterns[J]. JCO Precis Oncol, 2021, 5(5): 1354−1376. doi: 10.1200/PO.21.00122.
|
| [19] |
WU Y L, LU S, CHENG Y, et al. Uncommon/rare mutations in non-small cell lung cancer: consensus and contention[J]. The Journal of Evidence-Based Medicine, 2023, 23(3): 129−139. [吴一龙, 陆舜, 程颖, 等. 非小细胞肺癌少见/罕见靶点: 共识与争鸣[J]. 循证医学, 2023, 23(3): 129−139] doi: 10.12019/j.issn.1671-5144.2023.03.001.
WU Y L, LU S, CHENG Y, et al. Uncommon/rare mutations in non-small cell lung cancer: consensus and contention[J]. The Journal of Evidence-Based Medicine, 2023, 23(3): 129−139. doi: 10.12019/j.issn.1671-5144.2023.03.001
|
| [20] |
CHRISTOPOULOS P, EKMAN S, GUISIER F, et al. 1381P TOGETHER: pooled real-world datasets of METex14 skipping NSCLC and adjusted comparison of upfront (chemo-)immunotherapy with tepotinib from VISION[J]. Ann Oncol, 2023, 34(S2): S792−S793. doi: 10.1016/j.annonc.2023.09.2414.
|
| [21] |
KRON A, SCHEFFLER M, WIESWEG M, et al. 1383P Efficacy of capmatinib compared to standard of care for German patients with locally advanced or metastatic NSCLC harboring METex14 mutations: results from the RECAP study[J]. Ann Oncol, 2023, 34(S2): S793−S794. doi: 10.1016/j.annonc.2023.09.2416.
|
| [22] |
WOLF J, SETO T, HAN J Y, et al. Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)[J]. Ann Oncol, 2018, 29(S8): VIII741−VIII742. doi: 10.1093/annonc/mdy424.090.
|
| [23] |
PASSARO A, LEIGHL N, BLACKHALL F, et al. ESMO expert consensus statements on the management of EGFR mutant non-small-cell lung cancer[J]. Ann Oncol, 2022, 33(5): 466−487. doi: 10.1016/j.annonc.2022.02.003.
|
| [24] |
The Society of Cancer Precision Medicine of Chinese Anti-Cancer Association, Lung Cancer Expert Group of Chinese Medical Journal. Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2022 edition)[J]. Chinese Journal of Oncology, 2022, 44(10): 1047−1065. [中国抗癌协会肿瘤精准治疗专业委员会, 中华医学会杂志社肺癌研究协作组. 晚期驱动基因阳性非小细胞肺癌免疫治疗专家共识(2022版)[J]. 中华肿瘤杂志, 2022, 44(10): 1047−1065] doi: 10.3760/cma.j.cn112152- 20220614-00416.
The Society of Cancer Precision Medicine of Chinese Anti-Cancer Association, Lung Cancer Expert Group of Chinese Medical Journal. Chinese expert consensus on immunotherapy for advanced non-small lung cancer with oncogenic driver mutations (2022 edition)[J]. Chinese Journal of Oncology, 2022, 44(10): 1047−1065. doi: 10.3760/cma.j.cn112152-20220614-00416
|
| [25] |
DI NOIA V, D'AVENI A, D'ARGENTO E, et al. Treating disease progression with osimertinib in EGFR-mutated non-small-cell lung cancer: novel targeted agents and combination strategies[J]. ESMO Open, 2021, 6(6): 100280. doi: 10.1016/j.esmoop.2021.100280.
|
| [26] |
CHOUDHURY N J, MARRA A, SUI J S Y, et al. Molecular biomarkers of disease outcomes and mechanisms of acquired resistance to first-line osimertinib in advanced EGFR-mutant lung cancers[J]. J Thorac Oncol, 2023, 18(4): 463−475. doi: 10.1016/j.jtho.2022.11.022.
|
| [27] |
CORTOT A, LE X N, SMIT E, et al. Safety of MET tyrosine kinase inhibitors in patients with MET exon 14 skipping non-small cell lung cancer: a clinical review[J]. Clin Lung Cancer, 2022, 23(3): 195−207. doi: 10.1016/j.cllc.2022.01.003.
|
| [28] |
ZHANG L, WANG Y S, LIN L Z, et al. Chinese multidisciplinary expert consensus on the management of adverse drug reactions associated with savolitinib[J]. Chinese Journal of Oncology, 2023, 45(4): 298−312. [张力, 王永生, 林丽珠, 等. 赛沃替尼相关不良反应管理的中国多学科专家共识[J]. 中华肿瘤杂志, 2023, 45(4): 298−312] doi: 10.3760/cma.j.cn112152- 20221226-00853.
ZHANG L, WANG Y S, LIN L Z, et al. Chinese multidisciplinary expert consensus on the management of adverse drug reactions associated with savolitinib[J]. Chinese Journal of Oncology, 2023, 45(4): 298−312. doi: 10.3760/cma.j.cn112152-20221226-00853
|
DownLoad: